Klotho Neurosciences, Inc.

NASDAQ:KLTOHealthcare · Biotechnology

Mkt Cap-

Float63.98M

Shares O/S-

Inst Own-

Dilution

Mkt Cap-

Float63.98M

O/S-

Inst Own-

Dilution

NASDAQ:KLTO

MCap-

Float63.98M

O/S-

Inst Own-

Dilution

Historical Data

Date	Open	High	Low	Close	Volume

Key Metrics

Market Cap--

Enterprise Value--

P/E Ratio--

Est. Net Cash/Share--

Institutional Ownership--

SectorHealthcare

IndustryBiotechnology

ExchangeNASDAQ

Country

IPO DateApr 29, 2022

Shares Outstanding-

Float63.98M

Company Overview

Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders. Their leading gene therapy assets encompass AMI-101, which is designed for the management or prevention of Alzheimer's disease, and AMI-202, aimed at treating or averting amyotrophic lateral sclerosis. Formerly known as Anew Medical, Inc., the company underwent a name change to Klotho Neurosciences, Inc. in September 2024.

The firm's main office is situated in Omaha, Nebraska.

Leadership

Joseph Sinkule

Founder, Chief Executive Officer, Chairman of the Board & Secretary

Jeffrey LeBlanc

Chief Financial Officer

Peter J. Moriarty

Chief Business Officer

Shalom Z. Hirschman

Medical Advisor & Director

Employees

Country

Sector

Healthcare

Website

klothoneuro.com

Analyst Coverage

No analyst coverage for this companyNo ratings, price targets, or covering firms on file.

Insider Trades

Insider	Title	Type	Shares	Value	Date
ZENTMAN SAMUEL M	Director	Grant/Award	350.0K	--	Mar 4, 2026
Hirschman Shalom	Director	Grant/Award	350.0K	--	Mar 4, 2026
McGarity Jon	Director	Grant/Award	350.0K	--	Mar 4, 2026
SINKULE JOSEPH	Chief Executive Officer	Grant/Award	2.50M	--	Mar 4, 2026
LeBlanc Jeff	Chief Financial Officer	Grant/Award	2.50M	--	Mar 4, 2026
El-Dada Riad Hussein	--	Grant/Award	350.0K	--	Mar 4, 2026

Shareholders

Institutional

(50)

Insiderⓘ

(6)

5%+ Owners

(3)

Unattributed (incl. retail)ⓘ

Top Shareholders

Name	Shares	%	Source
Strategic EP, LLC · filed Mar 2026	0+6.7M via warrants	5.5%	13G
SINKULE JOSEPH Chief Executive Officer, Director	6.3M	--	FORM 4
METEORA CAPITAL, LLC	5.4M	--	13F
CITADEL ADVISORS LLC	5.2M	--	13F
VANGUARD CAPITAL MANAGEMENT LLC	3.0M	--	13F
Chardan Capital Markets LLC · may incl. warrants· stale · filed Jun 2024	2.0M	12.9%	13G
Austria Capital LLC · may incl. warrants· filed Jul 2025	1.6M	5.0%	13G
ARISTEIA CAPITAL, L.L.C. KLTOW	1.1M	--	13F
ZENTMAN SAMUEL M Director	1.1M	--	FORM 4
GEODE CAPITAL MANAGEMENT, LLC	1.0M	--	13F